Oncotarget

Research Papers:

Long noncoding RNA MALAT-1 is a novel inflammatory regulator in human systemic lupus erythematosus

Huaxia Yang, Naixin Liang _, Min Wang, Yunyun Fei, Jian Sun, Zhiyuan Li, Yuan Xu, Chao Guo, Zhili Cao, Shanqing Li and Yuchen Jiao

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:77400-77406. https://doi.org/10.18632/oncotarget.20490

Metrics: PDF 2396 views  |   HTML 3457 views  |   ?  


Abstract

Huaxia Yang1,*, Naixin Liang2,*, Min Wang1,*, Yunyun Fei1, Jian Sun3, Zhiyuan Li3, Yuan Xu2, Chao Guo2, Zhili Cao2, Shanqing Li2 and Yuchen Jiao4

1Department of Rheumatology and Clinical Immunology, Clinical Immunology Center, The Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2Department of Thoracic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

3Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

4National Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences Cancer Hospital, Beijing, China

*These authors have contributed equally to this work

Correspondence to:

Naixin Liang, email: [email protected]

Keywords: MALAT-1, lncRNA, SLE, PBMC, IL-21

Received: May 24, 2017     Accepted: July 24, 2017     Published: August 24, 2017

ABSTRACT

Despite growing evidence that Long noncoding RNAs (lncRNAs) can regulate gene expression and widely take part in autoimmune and inflammatory diseases, our knowledge of systemic lupus erythematosus (SLE)-related lincRNAs remains limited. In this study, we aimed to explore the contribution of the lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) to the pathogenesis of SLE. PBMCs were obtained from SLE patients and healthy donors. The expression levels of MALAT-1 were measured by quantitative PCR. Small interfering RNA (siRNA) was then used to knock down the expression of MALAT1 in order to determine the role of MALAT1 in the expression levels of IL-21 and SIRT1 signaling pathway in primary monocytes of SLE patients. Here, we found MALAT-1 expression was abnormally increased in SLE patients and predominantly expressed in human monocytes. Additionally, silencing MALAT-1 significantly reduced the expression of IL-21 in primary monocytes of SLE patients. Furthermore, MALAT-1 exerts its detrimental effects by regulating SIRT1 signaling. Our results demonstrate that MALAT-1 is the key regulatory factor in the pathogenesis of SLE and provides potentially novel target for therapeutic intervention.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20490